Abstract
Система комплексной поддержки и сопровождения научного журнала Elpub позволяет запустить двуязычный сайт журнала со встроенной системой электронной редакции в соответствии с лучшими издательскими практиками, а так же предусматривает техническую и методическую поддержку со стороны специалистов НЭИКОН.
Highlights
Objective: to evaluate the impact of tocilizumab (TCZ) therapy on the level of acute-phase indicators, autoantibodies, and immunoglobulins (Ig) G, M, and A after 2, 4, 8, 12, and 24 weeks as compared to the clinical efficacy of TCZ using DAS 28, SDAI, and CDAI scores and to reveal the immunological predictors of effective TCZ therapy
Erythrocyte sedimentation rate (ESR) was determined by the Westergren method; the levels of C-reactive protein (CRP), IgM rheumatoid factor (RF), IgG, IgM, and IgA were measured by a nephelometric method; the content of anti-cyclic citrullinated peptide antibodies was estimated by an electrochemiluminescence technique
At week 2 of TCZ therapy, there was a reduction in the levels of CRP to 0.5 (0.3; 1) mg/l, IgM RF to 191.5 (45.6; 507.5) IU/ml, IgA RF to 225.8 (74.2; 547.4) IU/ml; at week 4, there were decreases in anti-MCV titers to 312.15 (81.2; 925.5) IU/ml, which remained until week 24 (p < 0.01)
Summary
Objective: to evaluate the impact of tocilizumab (TCZ) therapy on the level of acute-phase indicators, autoantibodies, and immunoglobulins (Ig) G, M, and A after 2, 4, 8, 12, and 24 weeks as compared to the clinical efficacy of TCZ using DAS 28, SDAI, and CDAI scores and to reveal the immunological predictors of effective TCZ therapy. Цель исследования – оценить динамику уровней СРБ, аутоантител (IgM/IgA РФ, АЦБ), иммуноглобулинов классов G, M и A через 2, 4, 8, 12 и 24 нед после начала лечения ТЦЗ в сопоставлении с клинической эффективностью ТЦЗ по индексам DAS 28, CDAI и SDAI; выявить клинико-иммунологические предикторы эффективной терапии ТЦЗ у больных РА.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
